Eversept Partners LP Has $30.21 Million Stake in Amarin Co. plc (NASDAQ:AMRN)

Eversept Partners LP decreased its stake in shares of Amarin Co. plc (NASDAQ:AMRN) by 24.4% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,558,065 shares of the biopharmaceutical company’s stock after selling 502,222 shares during the quarter. Amarin comprises about 8.6% of Eversept Partners LP’s portfolio, making the stock its 2nd largest holding. Eversept Partners LP’s holdings in Amarin were worth $30,211,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the stock. Mcclain Value Management LLC boosted its position in shares of Amarin by 2.5% during the second quarter. Mcclain Value Management LLC now owns 23,431 shares of the biopharmaceutical company’s stock worth $454,000 after acquiring an additional 577 shares during the last quarter. Global Retirement Partners LLC lifted its position in Amarin by 30.7% during the first quarter. Global Retirement Partners LLC now owns 3,414 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 802 shares during the last quarter. West Chester Capital Advisors Inc. lifted its position in Amarin by 1.4% during the second quarter. West Chester Capital Advisors Inc. now owns 60,607 shares of the biopharmaceutical company’s stock valued at $1,175,000 after purchasing an additional 815 shares during the last quarter. US Bancorp DE lifted its position in Amarin by 16.0% during the second quarter. US Bancorp DE now owns 6,229 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 858 shares during the last quarter. Finally, Glen Harbor Capital Management LLC lifted its position in Amarin by 4.0% during the second quarter. Glen Harbor Capital Management LLC now owns 22,616 shares of the biopharmaceutical company’s stock valued at $439,000 after purchasing an additional 880 shares during the last quarter. Hedge funds and other institutional investors own 47.94% of the company’s stock.

Several research firms have commented on AMRN. Zacks Investment Research lowered shares of Amarin from a “buy” rating to a “hold” rating in a research report on Wednesday, July 24th. Stifel Nicolaus reiterated a “buy” rating and set a $26.00 price objective on shares of Amarin in a research report on Wednesday, July 31st. Jefferies Financial Group set a $30.00 price objective on shares of Amarin and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Leerink Swann set a $26.00 target price on shares of Amarin and gave the company a “buy” rating in a research note on Tuesday. Finally, Cantor Fitzgerald set a $35.00 target price on shares of Amarin and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Three equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $29.50.

In related news, Director Lars Ekman sold 91,016 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $15.01, for a total value of $1,366,150.16. Following the transaction, the director now owns 13,500 shares of the company’s stock, valued at approximately $202,635. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Aaron Berg sold 113,195 shares of the firm’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $18.59, for a total transaction of $2,104,295.05. The disclosure for this sale can be found here. Insiders sold a total of 659,202 shares of company stock worth $13,058,754 in the last ninety days. 2.75% of the stock is currently owned by insiders.

Shares of AMRN traded up $0.08 during midday trading on Friday, hitting $16.83. The stock had a trading volume of 69,637 shares, compared to its average volume of 6,576,359. Amarin Co. plc has a 1 year low of $2.65 and a 1 year high of $23.91. The firm has a market cap of $5.83 billion, a PE ratio of -42.87 and a beta of 1.27. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.01 and a quick ratio of 1.76. The stock’s 50 day moving average is $16.08 and its 200 day moving average is $18.42.

Amarin (NASDAQ:AMRN) last announced its earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $0.01. Amarin had a negative net margin of 27.51% and a negative return on equity of 111.75%. The business had revenue of $100.40 million for the quarter, compared to the consensus estimate of $99.54 million. During the same quarter in the prior year, the firm posted ($0.10) earnings per share. The business’s revenue for the quarter was up 90.9% on a year-over-year basis. As a group, equities research analysts expect that Amarin Co. plc will post -0.2 earnings per share for the current fiscal year.

About Amarin

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.

See Also: Day Trading

Want to see what other hedge funds are holding AMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amarin Co. plc (NASDAQ:AMRN).

Institutional Ownership by Quarter for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.